Enzymology |
Proteolytic activity of Clostridium difficile. |
Seddon SV, Borriello SP |
J Med Microbiol |
10.1099/00222615-36-5-307 |
1992 |
* |
Metabolism |
Comparative sequence analysis of the Clostridium difficile toxins A and B. |
von Eichel-Streiber C, Laufenberg-Feldmann R, Sartingen S, Schulze J, Sauerborn M |
Mol Gen Genet |
10.1007/BF00587587 |
1992 |
* |
Pathogenicity |
Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B. |
Flegel WA, Muller F, Daubener W, Fischer HG, Hadding U, Northoff H |
Infect Immun |
10.1128/iai.59.10.3659-3666.1991 |
1991 |
* |
Pathogenicity |
Molecular characterization of the Clostridium difficile toxin A gene. |
Dove CH, Wang SZ, Price SB, Phelps CJ, Lyerly DM, Wilkins TD, Johnson JL |
Infect Immun |
10.1128/iai.58.2.480-488.1990 |
1990 |
* |
Enzymology |
Purification of two high molecular weight toxins of Clostridium difficile which are antigenically related. |
von Eichel-Streiber C, Harperath U, Bosse D, Hadding U |
Microb Pathog |
10.1016/0882-4010(87)90073-8 |
1987 |
* |
Pathogenicity |
Evolution of the caecal epithelial barrier during Clostridium difficile infection in the mouse. |
Heyman M, Corthier G, Lucas F, Meslin JC, Desjeux JF |
Gut |
10.1136/gut.30.8.1087 |
1989 |
* |
Enzymology |
Cloning and characterization of overlapping DNA fragments of the toxin A gene of clostridium difficile. |
von Eichel-Streiber C, Suckau D, Wachter M, Hadding U |
J Gen Microbiol |
10.1099/00221287-135-1-55 |
1989 |
* |
Pathogenicity |
Clostridium difficile toxins A and B inhibit human immune response in vitro. |
Daubener W, Leiser E, von Eichel-Streiber C, Hadding U |
Infect Immun |
10.1128/iai.56.5.1107-1112.1988 |
1988 |
* |
Pathogenicity |
Differential cytotoxic effects of toxins A and B isolated from Clostridium difficile. |
Rothman SW, Brown JE, Diecidue A, Foret DA |
Infect Immun |
10.1128/iai.46.2.324-331.1984 |
1984 |
* |
Pathogenicity |
Closing in on the toxic domain through analysis of a variant Clostridium difficile cytotoxin B. |
von Eichel-Streiber C, Meyer zu Heringdorf D, Habermann E, Sartingen S |
Mol Microbiol |
10.1111/j.1365-2958.1995.mmi_17020313.x |
1995 |
* |
Metabolism |
Enhanced fermentation of mannitol and release of cytotoxin by Clostridium difficile in alkaline culture media. |
Kazamias MT, Sperry JF |
Appl Environ Microbiol |
10.1128/aem.61.6.2425-2427.1995 |
1995 |
* |
Pathogenicity |
Toxin production by Clostridium difficile in a defined medium with limited amino acids. |
Yamakawa K, Kamiya S, Meng XQ, Karasawa T, Nakamura S |
J Med Microbiol |
10.1099/00222615-41-5-319 |
1994 |
* |
Pathogenicity |
Haemagglutination activity of toxigenic and non-toxigenic strains of Clostridium difficile. |
Meng XQ, Yamakawa K, Ogura H, Nakamura S |
FEMS Microbiol Lett |
10.1111/j.1574-6968.1994.tb06816.x |
1994 |
* |
Pathogenicity |
Serogroup F strains of Clostridium difficile produce toxin B but not toxin A. |
Depitre C, Delmee M, Avesani V, L'Haridon R, Roels A, Popoff M, Corthier G |
J Med Microbiol |
10.1099/00222615-38-6-434 |
1993 |
* |
Enzymology |
The toxigenic element of Clostridium difficile strain VPI 10463. |
Hammond GA, Johnson JL |
Microb Pathog |
10.1016/s0882-4010(95)90263-5 |
1995 |
* |
Stress |
[Study of the thermoresistance of Clostridium difficile spores]. |
Meisel-Mikolajczyk F, Kaliszuk-Kaminska E, Martirosian G |
Med Dosw Mikrobiol |
|
1995 |
* |
Pathogenicity |
Definition of the single integration site of the pathogenicity locus in Clostridium difficile. |
Braun V, Hundsberger T, Leukel P, Sauerborn M, von Eichel-Streiber C |
Gene |
10.1016/s0378-1119(96)00398-8 |
1996 |
* |
Pathogenicity |
Positive regulation of Clostridium difficile toxins. |
Moncrief JS, Barroso LA, Wilkins TD |
Infect Immun |
10.1128/IAI.65.3.1105-1108.1997 |
1997 |
* |
Enzymology |
Transcriptional analysis of the toxigenic element of Clostridium difficile. |
Hammond GA, Lyerly DM, Johnson JL |
Microb Pathog |
10.1006/mpat.1996.0100 |
1997 |
* |
Pathogenicity |
Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. |
Hundsberger T, Braun V, Weidmann M, Leukel P, Sauerborn M, von Eichel-Streiber C |
Eur J Biochem |
10.1111/j.1432-1033.1997.t01-1-00735.x |
1997 |
* |
Pathogenicity |
Effect of isoleucine on toxin production by Clostridium difficile in a defined medium. |
Ikeda D, Karasawa T, Yamakawa K, Tanaka R, Namiki M, Nakamura S |
Zentralbl Bakteriol |
10.1016/s0934-8840(98)80174-6 |
1998 |
* |
Pathogenicity |
Laboratory diagnosis of toxigenic Clostridium difficile by polymerase chain reaction: presence of toxin genes and their stable expression in toxigenic isolates from Japanese individuals. |
Karasawa T, Nojiri T, Hayashi Y, Maegawa T, Yamakawa K, Wang XM, Nakamura S |
J Gastroenterol |
10.1007/s005350050214 |
1999 |
* |
Metabolism |
Detection and transcription of toxin DNA in a nontoxigenic strain of Clostridium difficile. |
Mathis JN, Pilkinton L, McMillin DE |
Curr Microbiol |
10.1007/pl00006811 |
1999 |
* |
Metabolism |
Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids. |
Karlsson S, Burman LG, Akerlund T |
Microbiology (Reading) |
10.1099/13500872-145-7-1683 |
1999 |
* |
Pathogenicity |
A nonsense mutation abrogates production of a functional enterotoxin A in Clostridium difficile toxinotype VIII strains of serogroups F and X. |
von Eichel-Streiber C, Zec-Pirnat I, Grabnar M, Rupnik M |
FEMS Microbiol Lett |
10.1111/j.1574-6968.1999.tb13773.x |
1999 |
* |
Pathogenicity |
Genetic characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates by PCR. |
Moncrief JS, Zheng L, Neville LM, Lyerly DM |
J Clin Microbiol |
10.1128/JCM.38.8.3072-3075.2000 |
2000 |
* |
Pathogenicity |
Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease. |
Sambol SP, Merrigan MM, Lyerly D, Gerding DN, Johnson S |
Infect Immun |
10.1128/IAI.68.10.5480-5487.2000 |
2000 |
* |
Metabolism |
Toxins, butyric acid, and other short-chain fatty acids are coordinately expressed and down-regulated by cysteine in Clostridium difficile. |
Karlsson S, Lindberg A, Norin E, Burman LG, Akerlund T |
Infect Immun |
10.1128/IAI.68.10.5881-5888.2000 |
2000 |
* |
Pathogenicity |
How to detect Clostridium difficile variant strains in a routine laboratory. |
Rupnik M |
Clin Microbiol Infect |
10.1046/j.1198-743x.2001.00290.x |
2001 |
* |
Metabolism |
Proteins released during high toxin production in Clostridium difficile. |
Mukherjee K, Karlsson S, Burman LG, Akerlund T |
Microbiology (Reading) |
10.1099/00221287-148-7-2245 |
2002 |
* |
Metabolism |
Expression of Clostridium difficile toxins A and B and their sigma factor TcdD is controlled by temperature. |
Karlsson S, Dupuy B, Mukherjee K, Norin E, Burman LG, Akerlund T |
Infect Immun |
10.1128/IAI.71.4.1784-1793.2003 |
2003 |
* |
Pathogenicity |
Immunological detection and cytotoxic properties of toxins from toxin A-positive, toxin B-positive Clostridium difficile variants. |
Blake JE, Mitsikosta F, Metcalfe MA |
J Med Microbiol |
10.1099/jmm.0.05404-0 |
2004 |
* |
Enzymology |
Simplified purification method for Clostridium difficile toxin A. |
Fu SW, Xue J, Zhang YL, Zhou DY |
World J Gastroenterol |
10.3748/wjg.v10.i18.2756 |
2004 |
* |
Enzymology |
LuxS/autoinducer-2 quorum sensing molecule regulates transcriptional virulence gene expression in Clostridium difficile. |
Lee AS, Song KP |
Biochem Biophys Res Commun |
10.1016/j.bbrc.2005.07.131 |
2005 |
* |
Phylogeny |
Co-infection of hamsters with toxin A or toxin B-deficient Clostridium difficile strains. |
Szczesny A, Martirosian G, Cohen S, Silva J Jr |
Pol J Microbiol |
|
2005 |
* |
Metabolism |
Difference in the cytotoxic effects of toxin B from Clostridium difficile strain VPI 10463 and toxin B from variant Clostridium difficile strain 1470. |
Huelsenbeck J, Dreger S, Gerhard R, Barth H, Just I, Genth H |
Infect Immun |
10.1128/IAI.01705-06 |
2006 |
* |
Pathogenicity |
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. |
Kokkotou E, Moss AC, Michos A, Espinoza D, Cloud JW, Mustafa N, O'Brien M, Pothoulakis C, Kelly CP |
Antimicrob Agents Chemother |
10.1128/AAC.01143-07 |
2008 |
* |
Metabolism |
Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. |
Rupnik M |
FEMS Microbiol Rev |
10.1111/j.1574-6976.2008.00110.x |
2008 |
* |
Pathogenicity |
Effects of anti-inflammatory drugs on fever and neutrophilia induced by Clostridium difficile toxin B. |
Cardoso RA, Filho AA, Melo MC, Lyerly DM, Wilkins TD, Lima AA, Ribeiro RA, Souza GE |
Mediators Inflamm |
10.1155/S0962935196000245 |
1996 |
* |
Genetics |
Comparative analysis of BI/NAP1/027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences. |
Stabler RA, Dawson LF, Phua LTH, Wren BW |
J Med Microbiol |
10.1099/jmm.0.47743-0 |
2008 |
* |
Metabolism |
Induction of toxins in Clostridium difficile is associated with dramatic changes of its metabolism. |
Karlsson S, Burman LG, Akerlund T |
Microbiology (Reading) |
10.1099/mic.0.2008/019778-0 |
2008 |
* |
Pathogenicity |
Truncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A. |
Murray R, Boyd D, Levett PN, Mulvey MR, Alfa MJ |
BMC Infect Dis |
10.1186/1471-2334-9-103 |
2009 |
* |
Phylogeny |
Clostridium difficile toxinotyping. |
Rupnik M |
Methods Mol Biol |
10.1007/978-1-60327-365-7_5 |
2010 |
* |
Metabolism |
Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. |
Merrigan M, Venugopal A, Mallozzi M, Roxas B, Viswanathan VK, Johnson S, Gerding DN, Vedantam G |
J Bacteriol |
10.1128/JB.00445-10 |
2010 |
* |
Metabolism |
Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. |
Babakhani F, Gomez A, Robert N, Sears P |
J Med Microbiol |
10.1099/jmm.0.029470-0 |
2011 |
* |
Pathogenicity |
Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile. |
Mathur T, Kumar M, Barman TK, Kumar GR, Kalia V, Singhal S, Raj VS, Upadhyay DJ, Das B, Bhatnagar PK |
J Antimicrob Chemother |
10.1093/jac/dkr033 |
2011 |
* |
Pathogenicity |
Efficacy of decontaminants and disinfectants against Clostridium difficile. |
Vohra P, Poxton IR |
J Med Microbiol |
10.1099/jmm.0.030288-0 |
2011 |
* |
Pathogenicity |
The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. |
Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB |
Gut Microbes |
10.4161/gmic.2.3.16333 |
2011 |
* |
Transcriptome |
Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. |
Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda C, Xavier J, Pamer EG |
Infect Immun |
10.1128/IAI.05496-11 |
2011 |
* |
Metabolism |
Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. |
Theriot CM, Koumpouras CC, Carlson PE, Bergin II, Aronoff DM, Young VB |
Gut Microbes |
10.4161/gmic.19142 |
2011 |
* |
Pathogenicity |
Induction of cytokines in a macrophage cell line by proteins of Clostridium difficile. |
Vohra P, Poxton IR |
FEMS Immunol Med Microbiol |
10.1111/j.1574-695X.2012.00952.x |
2012 |
* |
Phylogeny |
Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. |
Reeves AE, Koenigsknecht MJ, Bergin IL, Young VB |
Infect Immun |
10.1128/IAI.00647-12 |
2012 |
* |
Pathogenicity |
Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. |
Warren CA, van Opstal EJ, Riggins MS, Li Y, Moore JH, Kolling GL, Guerrant RL, Hoffman PS |
Antimicrob Agents Chemother |
10.1128/AAC.00877-12 |
2012 |
* |
Pathogenicity |
Fidaxomicin inhibits toxin production in Clostridium difficile. |
Babakhani F, Bouillaut L, Sears P, Sims C, Gomez A, Sonenshein AL |
J Antimicrob Chemother |
10.1093/jac/dks450 |
2012 |
* |
Metabolism |
Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment. |
Li Y, Figler RA, Kolling G, Bracken TC, Rieger J, Stevenson RW, Linden J, Guerrant RL, Warren CA |
BMC Infect Dis |
10.1186/1471-2334-12-342 |
2012 |
* |
Pathogenicity |
Difference in F-actin depolymerization induced by toxin B from the Clostridium difficile strain VPI 10463 and toxin B from the variant Clostridium difficile serotype F strain 1470. |
May M, Wang T, Muller M, Genth H |
Toxins (Basel) |
10.3390/toxins5010106 |
2013 |
* |
Pathogenicity |
Intestinal epithelial restitution after TcdB challenge and recovery from Clostridium difficile infection in mice with alanyl-glutamine treatment. |
Rodrigues RS, Oliveira RA, Li Y, Zaja-Milatovic S, Costa LB, Braga Neto MB, Kolling GL, Lima AA, Guerrant RL, Warren CA |
J Infect Dis |
10.1093/infdis/jit041 |
2013 |
* |
Pathogenicity |
Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease. |
Ghose C, Verhagen JM, Chen X, Yu J, Huang Y, Chenesseau O, Kelly CP, Ho DD |
Infect Immun |
10.1128/IAI.01074-12 |
2013 |
* |
Phylogeny |
A unique strain of community-acquired Clostridium difficile in severe complicated infection and death of a young adult. |
Heslop OD, Roye-Green K, Coard K, Mulvey MR |
BMC Infect Dis |
10.1186/1471-2334-13-299 |
2013 |
* |
Pathogenicity |
In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. |
Leeds JA, Sachdeva M, Mullin S, Barnes SW, Ruzin A |
J Antimicrob Chemother |
10.1093/jac/dkt302 |
2013 |
* |
Pathogenicity |
Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. |
Garneau JR, Valiquette L, Fortier LC |
BMC Infect Dis |
10.1186/1471-2334-14-29 |
2014 |
* |
Metabolism |
Spore formation and toxin production in Clostridium difficile biofilms. |
Semenyuk EG, Laning ML, Foley J, Johnston PF, Knight KL, Gerding DN, Driks A |
PLoS One |
10.1371/journal.pone.0087757 |
2014 |
* |
Pathogenicity |
Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection. |
Bassis CM, Theriot CM, Young VB |
Antimicrob Agents Chemother |
10.1128/AAC.02262-13 |
2014 |
* |
Metabolism |
Haemorrhagic toxin and lethal toxin from Clostridium sordellii strain vpi9048: molecular characterization and comparative analysis of substrate specificity of the large clostridial glucosylating toxins. |
Genth H, Pauillac S, Schelle I, Bouvet P, Bouchier C, Varela-Chavez C, Just I, Popoff MR |
Cell Microbiol |
10.1111/cmi.12321 |
2014 |
* |
Pathogenicity |
An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo. |
Baliban SM, Michael A, Shammassian B, Mudakha S, Khan AS, Cocklin S, Zentner I, Latimer BP, Bouillaut L, Hunter M, Marx P, Sardesai NY, Welles SL, Jacobson JM, Weiner DB, Kutzler MA |
Infect Immun |
10.1128/IAI.01950-14 |
2014 |
* |
Phylogeny |
An in vitro culture model to study the dynamics of colonic microbiota in Syrian golden hamsters and their susceptibility to infection with Clostridium difficile. |
Miezeiewski M, Schnaufer T, Muravsky M, Wang S, Caro-Aguilar I, Secore S, Thiriot DS, Hsu C, Rogers I, DeSantis T, Kuczynski J, Probst AJ, Chehoud C, Steger R, Warrington J, Bodmer JL, Heinrichs JH |
ISME J |
10.1038/ismej.2014.127 |
2014 |
* |
Metabolism |
Clostridium difficile-induced colitis in mice is independent of leukotrienes. |
Trindade BC, Theriot CM, Leslie JL, Carlson PE Jr, Bergin IL, Peters-Golden M, Young VB, Aronoff DM |
Anaerobe |
10.1016/j.anaerobe.2014.09.006 |
2014 |
* |
Pathogenicity |
Persistence and toxin production by Clostridium difficile within human intestinal organoids result in disruption of epithelial paracellular barrier function. |
Leslie JL, Huang S, Opp JS, Nagy MS, Kobayashi M, Young VB, Spence JR |
Infect Immun |
10.1128/IAI.02561-14 |
2014 |
* |
Metabolism |
The role of Gr-1(+) cells and tumour necrosis factor-alpha signalling during Clostridium difficile colitis in mice. |
McDermott AJ, Higdon KE, Muraglia R, Erb-Downward JR, Falkowski NR, McDonald RA, Young VB, Huffnagle GB |
Immunology |
10.1111/imm.12425 |
2015 |
* |
Metabolism |
Clostridium difficile infection aggravates colitis in interleukin 10-deficient mice. |
Kim MN, Koh SJ, Kim JM, Im JP, Jung HC, Kim JS |
World J Gastroenterol |
10.3748/wjg.v20.i45.17084 |
2014 |
* |
Metabolism |
Dynamics and establishment of Clostridium difficile infection in the murine gastrointestinal tract. |
Koenigsknecht MJ, Theriot CM, Bergin IL, Schumacher CA, Schloss PD, Young VB |
Infect Immun |
10.1128/IAI.02768-14 |
2014 |
* |
Metabolism |
Bacillus amyloliquefaciens as prophylactic treatment for Clostridium difficile-associated disease in a mouse model. |
Geeraerts S, Ducatelle R, Haesebrouck F, Van Immerseel F |
J Gastroenterol Hepatol |
10.1111/jgh.12957 |
2015 |
* |
Pathogenicity |
Defined Nutrient Diets Alter Susceptibility to Clostridium difficile Associated Disease in a Murine Model. |
Moore JH, Pinheiro CC, Zaenker EI, Bolick DT, Kolling GL, van Opstal E, Noronha FJ, De Medeiros PH, Rodriguez RS, Lima AA, Guerrant RL, Warren CA |
PLoS One |
10.1371/journal.pone.0131829 |
2015 |
* |
Pathogenicity |
Interleukin-23 (IL-23), independent of IL-17 and IL-22, drives neutrophil recruitment and innate inflammation during Clostridium difficile colitis in mice. |
McDermott AJ, Falkowski NR, McDonald RA, Pandit CR, Young VB, Huffnagle GB |
Immunology |
10.1111/imm.12545 |
2015 |
* |
Pathogenicity |
Memory B Cells Encode Neutralizing Antibody Specific for Toxin B from the Clostridium difficile Strains VPI 10463 and NAP1/BI/027 but with Superior Neutralization of VPI 10463 Toxin B. |
Devera TS, Lang GA, Lanis JM, Rampuria P, Gilmore CL, James JA, Ballard JD, Lang ML |
Infect Immun |
10.1128/IAI.00011-15 |
2015 |
* |
Pathogenicity |
Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model. |
Moore JH 2nd, van Opstal E, Kolling GL, Shin JH, Bogatcheva E, Nikonenko B, Einck L, Phipps AJ, Guerrant RL, Protopopova M, Warren CA |
J Antimicrob Chemother |
10.1093/jac/dkv479 |
2016 |
* |
Pathogenicity |
Vancomycin Treatment Alters Humoral Immunity and Intestinal Microbiota in an Aged Mouse Model of Clostridium difficile Infection. |
van Opstal E, Kolling GL, Moore JH 2nd, Coquery CM, Wade NS, Loo WM, Bolick DT, Shin JH, Erickson LD, Warren CA |
J Infect Dis |
10.1093/infdis/jiw071 |
2016 |
* |
Pathogenicity |
Effect of oligosaccharides on the adhesion of gut bacteria to human HT-29 cells. |
Altamimi M, Abdelhay O, Rastall RA |
Anaerobe |
10.1016/j.anaerobe.2016.03.010 |
2016 |
* |
Metabolism |
Probiotic Saccharomyces boulardii CNCM I-745 prevents outbreak-associated Clostridium difficile-associated cecal inflammation in hamsters. |
Koon HW, Su B, Xu C, Mussatto CC, Tran DH, Lee EC, Ortiz C, Wang J, Lee JE, Ho S, Chen X, Kelly CP, Pothoulakis C |
Am J Physiol Gastrointest Liver Physiol |
10.1152/ajpgi.00150.2016 |
2016 |
* |
Pathogenicity |
Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains. |
Secore S, Wang S, Doughtry J, Xie J, Miezeiewski M, Rustandi RR, Horton M, Xoconostle R, Wang B, Lancaster C, Kristopeit A, Wang SC, Christanti S, Vitelli S, Gentile MP, Goerke A, Skinner J, Strable E, Thiriot DS, Bodmer JL, Heinrichs JH |
PLoS One |
10.1371/journal.pone.0170640 |
2017 |
* |
Pathogenicity |
Toxin-positive Clostridium difficile latently infect mouse colonies and protect against highly pathogenic C. difficile. |
Etienne-Mesmin L, Chassaing B, Adekunle O, Mattei LM, Bushman FD, Gewirtz AT |
Gut |
10.1136/gutjnl-2016-313510 |
2017 |
* |
Pathogenicity |
Clostridium difficile-derived membrane vesicles induce the expression of pro-inflammatory cytokine genes and cytotoxicity in colonic epithelial cells in vitro. |
Nicholas A, Jeon H, Selasi GN, Na SH, Kwon HI, Kim YJ, Choi CW, Kim SI, Lee JC |
Microb Pathog |
10.1016/j.micpath.2017.03.006 |
2017 |
* |
Pathogenicity |
A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection. |
Ratsep M, Koljalg S, Sepp E, Smidt I, Truusalu K, Songisepp E, Stsepetova J, Naaber P, Mikelsaar RH, Mikelsaar M |
Anaerobe |
10.1016/j.anaerobe.2017.03.019 |
2017 |
* |
Pathogenicity |
Clostridium difficile Toxoid Vaccine Candidate Confers Broad Protection against a Range of Prevalent Circulating Strains in a Nonclinical Setting. |
Quemeneur L, Petiot N, Arnaud-Barbe N, Hessler C, Pietrobon PJ, Londono-Hayes P |
Infect Immun |
10.1128/IAI.00742-17 |
2018 |
* |
Pathogenicity |
A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection. |
Negm OH, Hamed M, Monaghan TM |
J Vis Exp |
10.3791/57399 |
2018 |
* |
Phylogeny |
Modified Mouse Model of Clostridioides difficile Infection as a Platform for Probiotic Efficacy Studies. |
De Wolfe TJ, Kates AE, Barko L, Darien BJ, Safdar N |
Antimicrob Agents Chemother |
10.1128/AAC.00111-19 |
2019 |
* |
Pathogenicity |
Toxin B Variants from Clostridium difficile Strains VPI 10463 and NAP1/027 Share Similar Substrate Profile and Cellular Intoxication Kinetics but Use Different Host Cell Entry Factors. |
Lopez-Urena D, Orozco-Aguilar J, Chaves-Madrigal Y, Ramirez-Mata A, Villalobos-Jimenez A, Ost S, Quesada-Gomez C, Rodriguez C, Papatheodorou P, Chaves-Olarte E |
Toxins (Basel) |
10.3390/toxins11060348 |
2019 |
* |
Pathogenicity |
Phenotypic characterisation of Clostridium difficile PCR ribotype 251, an emerging multi-locus sequence type clade 2 strain in Australia. |
Hong S, Knight DR, Chang B, Carman RJ, Riley TV |
Anaerobe |
10.1016/j.anaerobe.2019.06.019 |
2019 |
* |
Pathogenicity |
Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027. |
Peng Z, Simeon R, Mitchell SB, Zhang J, Feng H, Chen Z |
mSphere |
10.1128/mSphere.00596-19 |
2019 |
* |
Pathogenicity |
Chemical Space Exploration around Thieno[3,2-d]pyrimidin-4(3H)-one Scaffold Led to a Novel Class of Highly Active Clostridium difficile Inhibitors. |
Shao X, AbdelKhalek A, Abutaleb NS, Velagapudi UK, Yoganathan S, Seleem MN, Talele TT |
J Med Chem |
10.1021/acs.jmedchem.9b01198 |
2019 |
* |
Pathogenicity |
Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence. |
Castro-Cordova P, Diaz-Yanez F, Munoz-Miralles J, Gil F, Paredes-Sabja D |
Anaerobe |
10.1016/j.anaerobe.2020.102149 |
2020 |
* |
Proteome |
Impact of subinhibitory concentrations of metronidazole on proteome of Clostridioides difficile strains with different levels of susceptibility. |
Doan TH, Yen-Nicolay S, Bernet-Camard MF, Martin-Verstraete I, Pechine S |
PLoS One |
10.1371/journal.pone.0241903 |
2020 |
* |
Pathogenicity |
Infection With Clostridioides difficile Attenuated Collagen-Induced Arthritis in Mice and Involved Mesenteric Treg and Th2 Polarization. |
Schmidt CJ, Wenndorf K, Ebbers M, Volzke J, Muller M, Strubing J, Kriebel K, Kneitz S, Kreikemeyer B, Muller-Hilke B |
Front Immunol |
10.3389/fimmu.2020.571049 |
2020 |
* |
Metabolism |
Receptor Binding Domains of TcdB from Clostridioides difficile for Chondroitin Sulfate Proteoglycan-4 and Frizzled Proteins Are Functionally Independent and Additive. |
Henkel D, Tatge H, Schottelndreier D, Tao L, Dong M, Gerhard R |
Toxins (Basel) |
10.3390/toxins12120736 |
2020 |
* |
Metabolism |
Detection and elimination of a novel non-toxigenic Clostridioides difficile strain from the microbiota of a mouse colony. |
Maslanka JR, Gu CH, Zarin I, Denny JE, Broadaway S, Fett B, Mattei LM, Walk ST, Abt MC |
Gut Microbes |
10.1080/19490976.2020.1851999 |
2020 |
* |
Pathogenicity |
Murine Intrarectal Instillation of Purified Recombinant Clostridioides difficile Toxins Enables Mechanistic Studies of Pathogenesis. |
Markham NO, Bloch SC, Shupe JA, Laubacher EN, Thomas AK, Kroh HK, Childress KO, Peritore-Galve FC, Washington MK, Coffey RJ, Lacy DB |
Infect Immun |
10.1128/IAI.00543-20 |
2021 |
* |
Pathogenicity |
A new phenothiazine derivate is active against Clostridioides difficile and shows low cytotoxicity. |
Ronco T, Aragao FM, Saaby L, Christensen JB, Permin A, Williams AR, Thamsborg SM, Olsen RH |
PLoS One |
10.1371/journal.pone.0258207 |
2021 |
* |
Metabolism |
Role of Pannexin-1-P2X7R signaling on cell death and pro-inflammatory mediator expression induced by Clostridioides difficile toxins in enteric glia. |
Loureiro AV, Moura-Neto LI, Martins CS, Silva PIM, Lopes MBS, Leitao RFC, Coelho-Aguiar JM, Moura-Neto V, Warren CA, Costa DVS, Brito GAC |
Front Immunol |
10.3389/fimmu.2022.956340 |
2022 |
* |
|
Binary toxin producing Clostridium difficile strains. |
Rupnik M, Grabnar M, Geric B |
Anaerobe |
10.1016/j.anaerobe.2003.09.002 |
2003 |
* |
|
Bacillus Coagulans GBI-30 (BC30) improves indices of Clostridium difficile-Induced colitis in mice. |
Fitzpatrick LR, Small JS, Greene WH, Karpa KD, Keller D |
Gut Pathog |
10.1186/1757-4749-3-16 |
2011 |
* |
|
Bacillus coagulans GBI-30, 6086 limits the recurrence of Clostridium difficile-Induced colitis following vancomycin withdrawal in mice. |
Fitzpatrick LR, Small JS, Greene WH, Karpa KD, Farmer S, Keller D |
Gut Pathog |
10.1186/1757-4749-4-13 |
2012 |
* |
|
Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination. |
Erikstrup LT, Aarup M, Hagemann-Madsen R, Dagnaes-Hansen F, Kristensen B, Olsen KE, Fuursted K |
BMJ Open Gastroenterol |
10.1136/bmjgast-2015-000038 |
2015 |
* |
|
The efficacy of thuricin CD, tigecycline, vancomycin, teicoplanin, rifampicin and nitazoxanide, independently and in paired combinations against Clostridium difficile biofilms and planktonic cells. |
Mathur H, Rea MC, Cotter PD, Hill C, Ross RP |
Gut Pathog |
10.1186/s13099-016-0102-8 |
2016 |
* |
|
Traditional Chinese Medicine QPYF as Preventive Treatment for Clostridium difficile Associated Diarrhea in a Mouse Model. |
Ya-Nan G, Jun W, Hao-Jun Z, Hong-Bing J, Ping L, Xin-Zhu L |
Evid Based Complement Alternat Med |
10.1155/2016/3759819 |
2016 |
* |
|
High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection. |
Monaghan TM, Negm OH, MacKenzie B, Hamed MR, Shone CC, Humphreys DP, Acharya KR, Wilcox MH |
Clin Exp Gastroenterol |
10.2147/CEG.S133939 |
2017 |
* |
|
Establishment of an Endogenous Clostridium difficile Rat Infection Model and Evaluation of the Effects of Clostridium butyricum MIYAIRI 588 Probiotic Strain. |
Oka K, Osaki T, Hanawa T, Kurata S, Sugiyama E, Takahashi M, Tanaka M, Taguchi H, Kamiya S |
Front Microbiol |
10.3389/fmicb.2018.01264 |
2018 |
* |
|
Protection against Clostridium difficile infection in a hamster model by oral vaccination using flagellin FliC-loaded pectin beads. |
Bruxelle JF, Tsapis N, Hoys S, Collignon A, Janoir C, Fattal E, Pechine S |
Vaccine |
10.1016/j.vaccine.2018.08.013 |
2018 |
* |
|
Protective Effect of Pediococcus pentosaceus LI05 Against Clostridium difficile Infection in a Mouse Model. |
Xu Q, Gu S, Chen Y, Quan J, Lv L, Chen D, Zheng B, Xu L, Li L |
Front Microbiol |
10.3389/fmicb.2018.02396 |
2018 |
* |
|
The Conserved Cys-2232 in Clostridioides difficile Toxin B Modulates Receptor Binding. |
Chung SY, Schottelndreier D, Tatge H, Fuhner V, Hust M, Beer LA, Gerhard R |
Front Microbiol |
10.3389/fmicb.2018.02314 |
2018 |
* |
|
Bacteroides fragilis Prevents Clostridium difficile Infection in a Mouse Model by Restoring Gut Barrier and Microbiome Regulation. |
Deng H, Yang S, Zhang Y, Qian K, Zhang Z, Liu Y, Wang Y, Bai Y, Fan H, Zhao X, Zhi F |
Front Microbiol |
10.3389/fmicb.2018.02976 |
2018 |
* |
|
Lactobacillus gasseri APC 678 Reduces Shedding of the Pathogen Clostridium difficile in a Murine Model. |
Quigley L, Coakley M, Alemayehu D, Rea MC, Casey PG, O'Sullivan O, Murphy E, Kiely B, Cotter PD, Hill C, Ross RP |
Front Microbiol |
10.3389/fmicb.2019.00273 |
2019 |
* |
|
Immunogenicity and Protection from Receptor-Binding Domains of Toxins as Potential Vaccine Candidates for Clostridium difficile. |
Luo D, Liu X, Xing L, Sun Y, Huang J, Zhang L, Li J, Wang H |
Vaccines (Basel) |
10.3390/vaccines7040180 |
2019 |
* |
|
Impact of Subinhibitory Concentrations of Metronidazole on Morphology, Motility, Biofilm Formation and Colonization of Clostridioides difficile. |
Doan TH, Bernet-Camard MF, Hoys S, Janoir C, Pechine S |
Antibiotics (Basel) |
10.3390/antibiotics11050624 |
2022 |
* |
|
Akkermansia muciniphila Ameliorates Clostridioides difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites. |
Wu Z, Xu Q, Gu S, Chen Y, Lv L, Zheng B, Wang Q, Wang K, Wang S, Xia J, Yang L, Bian X, Jiang X, Zheng L, Li L |
Front Microbiol |
10.3389/fmicb.2022.841920 |
2022 |
* |
|
Efficacy of Omadacycline or Vancomycin Combined with Germinants for Preventing Clostridioides difficile Relapse in a Murine Model. |
Budi ND, Godfrey JJ, Safdar N, Shukla SK, Rose WE |
J Infect Dis |
10.1093/infdis/jiac324 |
2022 |
* |
|
The impact of dietary fibers on Clostridioides difficile infection in a mouse model. |
Wu Z, Xu Q, Wang Q, Chen Y, Lv L, Zheng B, Yan R, Jiang H, Shen J, Wang S, Wang K, Xia J, Han S, Li L |
Front Cell Infect Microbiol |
10.3389/fcimb.2022.1028267 |
2022 |
* |